Reslizumab as add-on therapy in patients with refractory asthma

BMJ Open Respir Res. 2020 Apr;7(1):e000494. doi: 10.1136/bmjresp-2019-000494.
No abstract available

Keywords: asthma; pulmonary eosinophilia.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use*
  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Adult
  • Aged
  • Anti-Asthmatic Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / drug therapy*
  • Child
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Eosinophilia / drug therapy*
  • Regression Analysis
  • Treatment Outcome
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists
  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • reslizumab